Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay
Authors:
- 5 May 2023
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 1224, 123738
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (ZIA BC 011267, ZIC SC 006,537)
- National Cancer Institute
This publication has 14 references indexed in Scilit:
- Are 90% of deaths from cancer caused by metastases?Cancer Medicine, 2019
- A Short Tandem Repeat-Enriched RNA Assembles a Nuclear Compartment to Control Alternative Splicing and Promote Cell SurvivalMolecular Cell, 2018
- Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancerCancer Chemotherapy and Pharmacology, 2018
- Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasisScience Translational Medicine, 2018
- Targeting metastasisNature Reviews Cancer, 2016
- Selecting the Correct Weighting Factors for Linear and Quadratic Calibration Curves with Least-Squares Regression Algorithm in Bioanalytical LC-MS/MS Assays and Impacts of Using Incorrect Weighting Factors on Curve Stability, Data Quality, and Assay PerformanceAnalytical Chemistry, 2014
- The perinucleolar compartmentJournal of Cellular Biochemistry, 2009
- Comparisons of Metastases in Different Organs: Biological and Clinical ImplicationsClinical Cancer Research, 2008
- Perinucleolar Compartment Prevalence Has an Independent Prognostic Value for Breast CancerCancer Research, 2005
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002